ChemWerth Revenue and Competitors

Woodbridge, CT USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • ChemWerth's estimated annual revenue is currently $38.6M per year.(i)
  • ChemWerth's estimated revenue per employee is $201,000

Employee Data

  • ChemWerth has 192 Employees.(i)
  • ChemWerth grew their employee count by 2% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$14.1M703%N/AN/A
#2
$1069.1M531918%N/AN/A
#3
$8M405%N/AN/A
#4
$9870.9M49109-6%N/AN/A
#5
$6M307%N/AN/A
#6
$101.1M50328%N/AN/A
#7
$9M4515%N/AN/A
#8
$29.3M1461%N/AN/A
#9
$38.6M1922%N/AN/A
#10
$8M403%N/AN/A
Add Company

Established in 1982, ChemWerth is a full service generic drug development and supply company providing high quality Active Pharmaceutical Ingredients to regulated markets worldwide.Through exclusive development and partnerships with API manufacturers, ChemWerth provides expertise in product selection & development; analytical and regulatory services and strong project management to ensure the highest standards of quality.

keywords:N/A

N/A

Total Funding

192

Number of Employees

$38.6M

Revenue (est)

2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ChemWerth News

2022-04-19 - Bivalirudin Market Size, Outlook And Forecast | Bachem, Teva ...

Bachem, Teva Pharmaceutical Industries, Ambiopharm, ChemWerth, ScinoPharm, Salubris, Suzhou No.4 Pharmaceutical Factory, SOHO-YIMING Pharmaceuticals.

2022-04-19 - Vecuronium Bromide Market Size, Outlook And Forecast ...

Jiupai Group, Credit Chemwerth Pharmaceutical, Beijing Xinze Medical Technology, Xianju Pharma, Jiangsu Nhwa Pharmaceutical. Vecuronium Bromide Market...

2022-04-19 - Paricalcitol Market Size 2022-2030| Key Players – Chemwerth ...

Paricalcitol Market Size 2022-2030| Key Players – Chemwerth Inc, Alp Pharm Beijing Co., Ltd, Chongqing Huapont Pharmaceutical Co. Ltd.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$30.4M202-13%$2M
#2
$50.4M20213%N/A
#3
$32.4M203-6%N/A
#4
$35M20616%N/A
#5
$58.2M215-4%N/A